Imatinib Mesylate Tablet, Film Coated
Product Images NDC 68001-623

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 68001-623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib-fig1 (Imatinib Fig1)

A progression-free survival graph comparing Imatinib Mesylate and IFN+Ara-C arms over 72 months since randomization. The y-axis shows percent without progression, and the x-axis shows months. The graph includes survival curves for each treatment group, with Imatinib Mesylate showing higher progression-free survival. An accompanying table lists patient numbers and hazard ratio statistics.*

FDA Label Image

Imatinib-fig2 (Imatinib Fig2)

A Kaplan-Meier curve titled "Figure 2: Time to Progression to AP or BC (ITT Principle)" showing the percentage of patients without progression to accelerated phase (AP) or blast crisis (BC) over 72 months since randomization. Two treatment arms are compared: Imatinib Mesylate and IFN+Ara-C, with Imatinib Mesylate arm showing higher progression-free survival. The chart also lists patient numbers, censored data, hazard ratio, and statistical significance (P<0.001).*

FDA Label Image

Figure (Imatinib Fig3)

A survival curve graph titled 'Study 1 Recurrence-Free Survival (ITT Population)' comparing Imatinib 400 mg and placebo. The y-axis represents the probability of being alive and recurrence-free, ranging from 0.0 to 1.0, while the x-axis shows survival time in months from 0 to 108. The graph includes censored data markers for both groups and a table of patient counts at risk over time intervals for Imatinib and placebo groups.*

FDA Label Image

Figure (Imatinib Fig4)

A Kaplan-Meier survival curve showing recurrence-free survival probability over time in months for two groups treated with Imatinib Mesylate. One group has a 12-month treatment duration, and the other has 36 months. The graph includes censored observations marked on the curves, a hazard ratio of 0.46, and p-value less than 0.0001 indicating statistical significance. Event counts and subjects at risk are provided below the x-axis.*

FDA Label Image

Figure (Imatinib Fig5)

A Kaplan-Meier survival curve chart titled 'Study 2 Overall Survival (ITT Population)' showing the probability of overall survival over time in months for two groups treated with Imatinib at 12 months and 36 months. The chart presents survival probabilities on the vertical axis and survival time in months on the horizontal axis, including statistics for hazard ratio, confidence interval, event numbers, and censored observations.*

FDA Label Image

Imatinib Mesylate Tabs 100mg 90 Tabs (Imatinib Fig6)

Imatinib Mesylate Tablets 100 mg film-coated tablet label from BluePoint Laboratories. The label includes warning, storage instructions, a note that the active ingredient is 119.5 mg imatinib mesylate equivalent to 100 mg imatinib free base, and a quantity of 90 tablets. Manufactured by Eugia Pharma Specialities Limited, made in India, with issuance date 08/2024.*

FDA Label Image

Imatinib Mesylate Tablets 400mg 30 Tabs (Imatinib Fig7)

Label for Imatinib Mesylate tablets, 400 mg strength, film-coated, oral dosage form by BluePoint Laboratories. The label includes storage instructions, dosage information referencing the prescribing information, manufacturer details as Eugia Pharma Specialities Limited made in India, and a 30-tablet count. It features the OncoPoint logo and an NDC barcode.*

FDA Label Image

Chemical Structure (Imatinib Str)

Chemical structure of Imatinib Mesylate, depicting the molecular arrangement of its atoms and functional groups as shown in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.